CJC 1295 Peptide Structure From Its Name to Its DAC Hook

The cjc 1295 peptide is a long acting copy of a brain hormone that tells the pituitary gland to release growth hormone. It was developed by a Canadian biotech company in the early 2000s, tested in small trials in 2006 and never approved. This stop explains what the molecule is, then reads the adverse events that were actually recorded, so that the record can be told apart from the rumours.

Reading the Name Letter by Letter

People ask what is cjc peptide because the letters look like a code, and they are. CJC is a developer code, and 1295 is the number of one compound in the program. The molecule is built on the first 29 amino acids of growth hormone releasing hormone, written GRF 1 to 29, because that short stretch carries the activity of the full hormone. The natural hormone is cleared within minutes, so chemists set out to make an analogue that lasts longer. The 1295 peptide is the result of that work. It fits the same receptor as the natural hormone, the GHRH receptor on pituitary cells, and so it belongs on the Signal line next to tesamorelin.

The name also causes confusion in the market. Some products labelled cjc ipamorelin or cjc/ipamorelin mix two separate molecules in one vial, and others use the shorthand cjc 1295 peptide for different versions of the chain. Ipamorelin is a different compound, a short peptide that acts at a growth hormone secretagogue receptor, a different lock. Mixing them was never tested as a combined product in a published trial. When a page says cjc-1295 and ipamorelin as if they were one drug, the page is describing a vendor blend, and the blend has no published record behind it. The same goes for pages that write about ipamorelin and cjc 1295 as a matched pair with a known schedule or a known list of effects, because no such list exists in the literature.

Four Substitutions and a Hook

The 2005 paper that introduced the molecule describes CJC-1295 as a tetrasubstituted GRF 1 to 29, meaning four of the 29 amino acids were swapped for others to make the chain harder for enzymes to cut. The most important enemy is DPP-IV, an enzyme that snips the front end of the natural hormone. The second change is a hook at the tail. A maleimide group sits on a lysine at the end of the chain, and it reacts with a free sulfur on albumin, the main carrier protein in blood. This is the DAC, short for drug affinity complex, and it ties the peptide to a protein that stays in the blood for weeks.

The result in rats was a compound that remained in plasma beyond three days and produced about four times more growth hormone release over two hours than the unmodified chain. In people, the 2006 studies estimated the half-life at roughly six to eight days. This matters for side effects, because a drug that lingers cannot be stopped once it is in the body, and its effects fade only as it clears. A version of the same chain without the hook behaves like a short acting peptide. The record on the long acting form should not be applied to it, or the other way around.

What the Recorded Trials Reported

Two papers from 2006 form the safety record. Teichman and colleagues ran two randomized, placebo controlled trials in healthy adults, lasting 28 and 49 days. They reported rises in growth hormone and IGF-1 that lasted days to over a week, and they wrote that no serious adverse reactions were reported and that the drug was safe and relatively well tolerated. Ionescu and Frohman then measured the pulses of growth hormone in healthy men a week after a single injection and found that pulses persisted while the low points between them rose. Neither abstract lists the minor effects, and this article does not claim to know them. Anyone wanting that list should read the full papers.

The record also has a darker line. In July 2006, news reports said the company stopped a phase 2 study in people with lipodystrophy after a participant died. The reports said the cause and any link to the drug were still being investigated, at the time. A death in a trial does not prove the drug caused it, and this article does not claim that it did. What it shows is that the molecule never reached the stage where a full safety picture exists, and the cjc-1295 side effects people discuss online are mostly guesses. Anyone who reads a confident list of effects for the cjc 1295 peptide should ask which trial it came from, because the honest answer is usually none.

Where the Regulator Wrote Its Warning

The FDA page on bulk drug substances that may pose significant safety risks for compounding lists CJC-1295 in a table of nominated substances that were withdrawn. The page states that serious adverse events were associated with it, including increased heart rate and a widening of blood vessels throughout the body, that available clinical data are limited, and that it may pose a risk of immunogenicity for some routes. Immunogenicity means that the body may make antibodies against a foreign peptide, which can cause reactions or reduce the effect. That entry is the closest thing to an official statement on cjc 1295 side effects, and it reads as a caution.

The same page records ipamorelin as a separate item. It notes serious adverse events including death when ipamorelin was given into a vein in a published study of gut motility, and says that for other routes the FDA lacks enough information to know whether harm would follow. So searches such as cjc ipamorelin side effects have two warnings to read, one per molecule, and none for the blend. A person who wants to explore this axis for a medical reason should ask a clinician about approved options, rather than relying on forum tables of cjc 1295 ipamorelin side effects that no trial supports.

Conclusion

The cjc 1295 peptide is a four substitution copy of GRF 1 to 29 with an albumin hook that stretches its action to days. Its small 2006 human studies reported no serious adverse reactions, a phase 2 trial was stopped after a death whose cause was under review, and the FDA lists safety concerns and limited data. It is not an approved drug.